BeiGene, Ltd. (BGNE) CMO Jane Huang Sells 600 Shares of Stock
BeiGene, Ltd. (NASDAQ:BGNE) CMO Jane Huang sold 600 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $85.00, for a total transaction of $51,000.00. Following the sale, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,516,500. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Jane Huang also recently made the following trade(s):
- On Monday, November 20th, Jane Huang sold 1,600 shares of BeiGene stock. The stock was sold at an average price of $86.25, for a total transaction of $138,000.00.
BeiGene, Ltd. (BGNE) opened at $84.87 on Tuesday. BeiGene, Ltd. has a one year low of $26.43 and a one year high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.
BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same quarter in the previous year, the company earned ($1.08) earnings per share. equities research analysts expect that BeiGene, Ltd. will post -3.09 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/21/beigene-ltd-bgne-cmo-jane-huang-sells-600-shares-of-stock.html.
Several analysts recently issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price objective (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. Zacks Investment Research raised shares of BeiGene from a “hold” rating to a “buy” rating and set a $115.00 price objective for the company in a report on Tuesday, October 3rd. Maxim Group reaffirmed a “buy” rating and set a $120.00 price objective (up from $77.00) on shares of BeiGene in a report on Thursday, September 28th. Cowen and Company reaffirmed a “buy” rating on shares of BeiGene in a report on Tuesday, November 14th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 price objective (up from $58.00) on shares of BeiGene in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $96.67.
Large investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new position in BeiGene during the 3rd quarter valued at $160,000. Teachers Retirement System of The State of Kentucky acquired a new position in BeiGene during the 3rd quarter valued at $248,000. SG Americas Securities LLC acquired a new position in BeiGene during the 2nd quarter valued at $111,000. Aperio Group LLC acquired a new position in BeiGene during the 3rd quarter valued at $301,000. Finally, Jane Street Group LLC acquired a new position in BeiGene during the 3rd quarter valued at $339,000. Hedge funds and other institutional investors own 57.07% of the company’s stock.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.